Full Picture

Article analysis:

The article "A view on drug resistance in cancer" published in Nature provides a comprehensive overview of the problem of drug resistance in cancer and proposes potential solutions. The authors take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics, tumour heterogeneity, physical barriers, the immune system and the microenvironment, undruggable cancer drivers, and the many consequences of applying therapeutic pressures.

The article presents a well-researched and informative analysis of the biological determinants of drug resistance in cancer. However, it is important to note that the article may have some biases. For example, it focuses primarily on pharmacological approaches to addressing drug resistance rather than considering alternative therapies such as lifestyle changes or complementary medicine. Additionally, while the article acknowledges that combination therapy often leads to disease becoming undetectable in HIV or cured in tuberculosis, it does not explore why this is not typically the case for metastatic cancers.

Furthermore, while the article proposes potential solutions to drug resistance such as earlier detection of tumours permitting cancer interception and adaptive monitoring during therapy, it does not provide sufficient evidence for their effectiveness. The proposed solutions are based on theoretical models rather than empirical data from clinical trials.

Another limitation of the article is its focus on genomic sequencing as a means of evaluating tumour heterogeneity. While genomic sequencing can provide valuable information about tumour heterogeneity, it is expensive and time-consuming. Other methods such as imaging techniques may also be useful for evaluating tumour heterogeneity but are not discussed in detail.

Overall, while "A view on drug resistance in cancer" provides valuable insights into the problem of drug resistance in cancer and proposes potential solutions, it is important to consider its limitations and biases when interpreting its findings. Further research is needed to determine the most effective strategies for addressing drug resistance in cancer.